Want to join the conversation?
$MYL, the biggest U.S. generic drug maker, said that with the Biocon partnership and Momenta collaboration, it now has a combined portfolio of 15 biosimilar and insulin analog generic products in development with a current total brand market value of more than $75Bil in worldwide sales.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.